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Abstract
Type 1 hyper IgE syndrome (HIES), also known as Job’s Syndrome, is an autosomal dominant disorder due to
defects in STAT3 signaling and Th17 differentiation. Symptoms may present during infancy but diagnosis is often
made in childhood or later. HIES is characterized by immunologic and non-immunologic findings such as recurrent
sinopulmonary infections, recurrent skin infections, multiple fractures, atopic dermatitis and characteristic facies.
These manifestations are accompanied by elevated IgE levels and reduced IL-17 producing CD3+CD4+ T cells.
Diagnosis in young children can be challenging as symptoms accumulate over time along with confounding
clinical dilemmas. A NIH clinical HIES scoring system was developed in 1999, and a more recent scoring system
with fewer but more pathogonomonic clinical findings was reported in 2010. These scoring systems can be used
as tools to help in grading the likelihood of HIES diagnosis. We report a young child ultimately presenting with
disseminated histoplasmosis and a novel STAT3 variant in the SH2 domain.
Introduction
Type 1 hyper IgE syndrome (HIES) is an autosomal
dominant disorder due to defects in signal transducer
and activator of transcription 3 (STAT3) signaling [1,2].
HIES was first described in 1966 and called Job’ss y n -
drome for the clinical manifestation of recurrent staphy-
lococcal abscesses [3]. The association with elevated IgE
levels was discovered in 1972 and was referred to as
Buckley syndrome [4] which was found to be the same
condition as Job’s syndrome. The genetic mutation of
HIES was discovered in 2007. Minegishi et al.a n dH o l -
land et al. reported heterozygous dominant-negative
mutations in STAT3 in the DNA-binding and SH2
domains [5,6]. STAT3 plays an important signaling role
in Th17 differentiation.
Type 1 HIES is characterized by immunologic and
non-immunologic findings. These manifestations are
accompanied by elevated IgE levels and reduced IL-17
producing CD3+CD4+ T cells. Immunologic findings
include newborn rash, recurrent sinopulmonary infec-
tions, recurrent skin infections, recurrent cyst-forming
pneumonias, eczema, mucocutaneous fungal disease,
eosinophilia and elevated IgE. Non-immunologic find-
ings include characteristic face, retained primary teeth,
multiple fractures, scoliosis, hyperextensibility, Chiari I
malformations and craniosynostosis.
Diagnosis in young children can be challenging as
symptoms accumulate over time along with confounding
clinical dilemmas. A clinical HIES scoring system by the
National Institutes of Health (NIH) was developed in
1999 [1]. A more recent scoring system with fewer but
more pathogonomonic clinical findings was reported in
2010 [2]. These scoring systems can be used as tools to
assess the likelihood of HIES diagnosis.
Also reported are autosomal recessive forms of HIES,
i.e. defects in dedicator of cytokinesis 8 protein
(DOCK8) and tyrosine kinase 2 (TYK2). These forms
are less common, mostly described in consanguineous
communities and have several different clinical
distinctions. * Correspondence: dlew@uthsc.edu
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This patient with wiry hair and square asymmetric face,
was initially hospitalized at 5 months of age for pneu-
monia, multiple fractures, eczema with facial folliculitis
but without cold abscess, wheezing, or milk allergy. Eva-
luation for non-accidental trauma was ongoing. Labora-
tory findings were as follows: IgE 187 IU/mL, IgA < 6.3
mg/dL, and eosinophil count 3,500/mm3. IgG, IgM,
lymphocyte mitogen stimulation and cell surface mar-
kers were normal. Family history was noncontributory.
His IgA normalized over the next 2 years. He had nine
subsequent hospitalizations due to the following issues:
rib fractures and pneumonia, respiratory distress sec-
ondary to subglottic cyst, gastroenteritis with dehydra-
tion, pneumonia requiring mechanical ventilation, severe
dysphagia/aspiration pneumonia requiring G-Tube/Nis-
sen fundoplication, and Streptococcus pneumoniae pneu-
monia with parapneumonic effusion. He also developed
pneumatoceles and required left thoracotomy with bleb
plication/pleurodesis. Other pertinent complications
included recurrent ear infections and thrush, develop-
mental delay, osteopenia, eczema, cellulitis, and allergic
sensitization to egg, cat and dust mites. Further evalua-
tion included normal chromosomes (46XY), CPK, vita-
min D, calcium, PTH, and sweat chloride, along with
negative HIV screening.
In July 2010, at 33 months of age, he presented with
hepatosplenomegaly, hypoxia and respiratory distress. A
diffuse opacity was seen on chest xray. Bronchoalveolar
lavage showed extracellular and intracellular yeast suspi-
cious for Histoplasma capsulatum. Disseminated histo-
plasmosis was confirmed by urine and serum antigen
levels (both above measurable test limit).
Due to disseminated infection and the complexity of
his clinical course, the question of primary immunodefi-
ciency was revisited. His IgE level on initial presentation
a t5m o n t h so fa g ew a s1 8 7I U / m L ,a n db y3 3m o n t h s
of age had increased to 1,106 IU/mL. The clinical score
for HIES progressed to 46 (Table 1). Dihydrorhodamine,
Mannan-binding-lectin, CH50 and mitogen stimulation
were normal. Pneumococcal titers were flat despite a
history of S. pneumoniae infection and vaccination with
3o u to f4P r e v n a r 7d o s e s .C e l ls u r f a c em a r k e r sw e r e
found to be normal except for slightly elevated activated
T cells at 12% and slightly decreased CD4+CD45+ RA-/
RO+ memory T cells at 15% with normal reference
range of 16-46%. Flow cytometric analysis of Th1 and
Th17 cells [performed by the Advanced Diagnostic
Immunology Laboratories National Jewish Health (Den-
ver, CO) as a research development study with a minor
modification (5 versus 6 hour stimulation) of the
method of Ma et al.] [7] revealed low Th17 or IL-17
producing cells (0.3% of CD4+ T cells; date-matched
normal control: 2.1%). Th17:Th1 ratio was also low
(9:1,000). STAT3 gene analysis revealed a missense
mutation in exon 20 within the Src-homology (SH2)
domain [c.1772A > T, amino acid change p.Lys591Met]
(Figure 1).
Informed consent was obtained and approved by
UTHSC IRB.
Discussion
We report a case of disseminated histoplasmosis in a
young child with STAT3-HIES [c.1772A > T, amino
acid change p.Lys591Met]. Our patient’s missense muta-
tion in the SH2 domain has not been previously
reported. Woellner et al. identified a missense mutation
in the same amino acid [c.1771A > G, amino acid
change p.Lys591Glu] but no clinical information is avail-
able [2].
Genetics
AD-HIES is now defined by heterozygous mutation
detection in STAT3 which contains 24 exons and 3
splice variants. STAT3 sequencing became commercially
available in mid-2009 which provides the opportunity
for more expedited and objective diagnosis but must be
weighed by the level of clinical suspicion due to health-
care cost burden. Over 95% of AD-HIES have detectable
STAT3 mutations and all domains have had mutations
described including the N-terminal, coiled-coil, DNA-
binding, linker[8], SH2 and transactivation domains.
Most of these mutations affect either the DNA-bind-
ing domain or the SH2 domain. Genotype-phenotype
correlations involving most common domains and















IgE score (IU/ml) 1 (187) 1 (371) 8 (1,011) 8 (1,106)
Skin abscess 0 0 0 2
Pneumonia 2 4 6 8
Lung anomalies 0 0 8 8
Fractures 4 4 4 8
Eczema 2 2 2 2
URIs/year 2 2 2 2
Candidiasis 1 1 1 1




NIH Score 19 19 36 46
Pneumonia N/A N/A 6 × 2.5 8 × 2.5
Pathologic fractures N/A N/A 4 × 3.33 8 × 3.33
STAT3 Score N/A N/A 28.32 46.64
NIH score: unlikely, < 20; indeterminate, 20-40; suggestive of AD-HIES, > 40
STAT3 score: possible, > 30+IgE ≥ 1,000 IU/ml, probable: > 30+IgE ≥ 1,000 IU/
ml + low Th17 and/or positive F.Hx; definitive, > 30+IgE ≥ 1,000 IU/ml +
heterozygous STAT3 mutation
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Sixty-five subjects (35 with DNA-binding domain muta-
tion and 30 with SH2 domain mutation) were evaluated
and suggest increased non-immunologic features in the
SH2 domain group including high palate, increased
interalar distance as well as increased scoliosis in a
younger patient subset. They also showed a possible
association with increased mortality risk secondary to
infection as 6 of the 7 infection related deaths had
DNA-binding domain mutations (five in the arginine
382 hotspot). Causative organisms were not reported
but a trend of increased Varicella-Zoster reactivation
was observed [9]. Although these findings are suggestive,
this sample size still lacks statistical power which has
been true in other studies as well [10,11]. Our patient
has a mutation in SH2 domain and does not have the
aforementioned non-immunologic findings, but over
time they could develop.
Role in infection
Disseminated histoplasmosis in HIES is rare and not yet
reported in young children. We found six case-reports
total (5 patients) in the literature of histoplasma infection
in HIES. Three had gastrointestinal tract disease (two
teenagers and one adult) [12]. One patient had laryngeal
h i s t o p l a s m ao n l y[ 1 1 ] .T h eo t h e rc a s e ,r e p o r t e dt w i c e ,
involves an adult male with budding yeast from a tongue
ulcer and histoplasma cultured from right middle lobe
infiltrate [11,13]. Invasive fungal disease in HIES is typi-
cally seen in adults and attributed to lung damage from
previous bacterial pneumonias [11]. Our patient devel-
oped pneumatoceles following pneumococcal pneumonia
that possibly served as a nidus for Histoplasma, which
ultimately disseminated. There are reports of other inva-
sive mycotic diseases [14]. These cases suggest increased
risk of disseminated fungal infection with endemic
mycoses in HIES patients, raising the possibility that
STAT3 has a role in intracellular infection.
Fungal pathogens are recognized by C-type lectin
receptors (Dectin-1, Dectin-2, macrophage-inducible C-
type lectin, mannose receptor), and there are recent
reports indicating variants of either these receptors or
down-stream signaling molecules will result in defective
NFkB function. NFkB normally promotes IL1b, IL-6 and
IL-23 cytokine production by macrophages [15]. These
macrophage cytokines facilitate STAT3 dependent Th17
cell differentiation. Th17 cells produce cytokines (i.e. IL-
17, IL-21, IL-22) crucial for host defense against bacteria
and fungi [15]. Thus if STAT3 signaling is defective, as
in HIES, Th17 differentiation is suppressed and there is
resultant susceptibility to opportunistic infection [15].
HIES and chronic mucocutaneous disease (CMCD)
share the clinical similarities of recurrent staphylococcal
and candidal skin infections resulting from defective
Th17 T cells. IL-17A and IL-17F are members of the
IL-17 family that seem to play an important role in pre-
vention of these infections. It has been recently reported
that deficits in IL-17 production result in defective sali-
vary activity due to antimicrobial protein impairment
suggested to play a major role in initial fungal defense
[16]. In addition, IL-22 stimulation results in bolstering
the innate response through its production of b-defen-
sins. Recently described autosomal recessive defect in
IL-17 receptor A (IL-17RA) and autosomal dominant
defect in IL-17F are both associated with increased sta-
phylococcal and candidal infections [17]. In HIES, “cold
boils” and recurrent pulmonary infections by Staphylo-
coccus aureus or Haemophilus influenza are common.
A commonly described opportunistic fungal infection
in primary immunodeficiency is Pneumocystis jiroveci
although it is more often described in T-cell immunode-
ficiences. Pj i r o v e c i(formerly P carinii) is an extracellu-
lar fungus that has been described in several patients
with HIES. Holland et al report seven HIES, HIV-nega-
tive patients with Pj i r o v e c ifound in respiratory or pul-
monary specimens [18]. Those patients still living
responded to appropriate therapy and were not contin-
ued on prophylaxis. Whether Pj i r o v e c isusceptibility in
HIES is due to preceding chronic lung disease or immu-
nologic abnormalities is not known. The IL-23-IL-17
Transactivation  SH2      Linker  DNA Binding  Coiled-coil  N 
K591M 
Figure 1 STAT3 Novel Variant.O u rp a t i e n t ’s mutation on a schematic primary structure of STAT3 gene. STAT3 analysis revealed a missense
mutation in exon 20 within the SH2 domain [c.1772A > T, amino acid change p.Lys591Met].
Robinson et al. Clinical and Molecular Allergy 2011, 9:14
http://www.clinicalmolecularallergy.com/content/9/1/14
Page 3 of 7cytokine axis is important in the murine model via IL-
23 leading to increased production of IL-17 and IL-22
[19,20]. Our patient did have BAL findings of extracellu-
lar yeast and thus was treated with three weeks of Bac-
trim, but he never had a definitive diagnosis of P jiroveci
pneumonia.
Scoring systems
As previously mentioned over 30 patients with HIES
were used to develop a clinical scoring system in 1999
(NIH-HIES score) [1]. A more recent scoring system
(referred to as the HIES STAT3 score) published in Feb-
ruary 2010 attempted to define clinical features that
were better predicators of genotype [2]. The authors
studied over 100 patients with presumed HIES and IgE
levels > 1,000 IU/mL to determine the five features that
comprise their criteria: pneumonia, newborn rash,
pathologic fractures, characteristic face of Job’ss y n -
drome and cathedral palate [2]. The terminology used is
more consistent with immunodeficiency diagnostic cri-
teria of other more studied diseases.
The newer scoring system also utilizes Th17 cell
counts in its diagnostic guidelines. Multiple groups have
shown reduced Th17 cell counts expressed as percen-
tage of CD4+ T cells in HIES [2,10,21,22]. This test is
not currently commercially available, but has been
shown helpful in differentiating between HIES versus
atopic dermatitis [22].
Our patient’s clinical scoring was recorded over time
and increased with sequential calculations. This trend
exemplifies how patients accrue symptoms over time
making early diagnosis in young children very difficult.
Confounders
Defects in STAT3 signaling and its pathobiologic impli-
cations on immunologic and non-immunologic path-
ways will not completely manifest upon initial
presentation. Development of additional symptoms over
time is the expectation in HIES. For this reason, the
NIH scoring system has a young age correction since
certain parameters (i.e. multiple pneumonias, retention
of primary teeth, scoliosis) will not be present until later
in life. Young children can often have additional con-
founding co-morbidities that lead to unnecessary evalua-
tions and delay in diagnosis.
Our patient’s symptoms could be attributed to other
possible etiologies. He had multiple rib fractures at dif-
ferent stages of healing that were suspicious for non-
accidental trauma. With his osteopenia, he was predis-
posed to increased risk for fractures. Additionally, his
multiple inhalant and food allergies could have contrib-
uted to eosinophilia and elevated IgE levels. Multiple
pneumonias in children with gastroesophageal reflux are
common due to aspiration. Our patient had severe
reflux that required G-tube and Nissen fundoplication.
As he was a late premature infant with a transiently low
IgA level, increased risk for infection was expected. Both
IgA and IL-17 responses are important in defense
against fungi [23]. Moreover, B cell immunoglobulin
production and Th17 cells can be primed by Dectin-1
[24], although we have not investigated the Dectin-1
response in our patient.
There are many pediatric diagnoses much more com-
m o nt h a nH I E St h a tc o u l de x p l a i nt h ea s p e c t so fo u r
patient’s presentation. Therefore, like our patient, young
c h i l d r e na r em o r ep r o n et oh a v ead e l a yi nd i a g n o s i s ,
whereas older children and adults will have accumulated
more hallmark symptoms. The total IgE level can trend
down to under 1,000 IU/mL, although values do not
correlate well with disease activity or severity. Thus,
clinical suspicion, coupled with scoring systems repeated
over time can facilitate ultimate diagnosis.
Management
As with most primary immunodeficiences without a
cure, AD-HIES management focuses on preventative
measures to limit the number and severity of infections.
Our patient will remain on indefinite prophylactic anti-
biotic and antifungal therapy. Although he initially
responded to booster with Prevnar 13, his immunity
waned over 9 months to only one protective titer. Insti-
tution of prophylactic antibiotics targeted against pyo-
g e n i cb a c t e r i a( n a m e l yStaphylococcus aureus)i s
paramount. Second-generation cephalosporins or tri-
methoprim/sulfamethoxazole are options for antibacter-
ial prophylaxis; however, if lungs have structural
damage, antimicrobial coverage is broadened to include
Pseudomonas. History of fungal infection requires pro-
phylactic treatment with fluconazole or itraconazole.
Aggressive treatment at the earliest sign of infection is
necessary to prevent serious illness. As these patients
m a yh a v eo n l ym i l ds y m p t o m sd u et oi m p a i r m e n to f
acute phase cytokines (i.e. IL-6), symptoms may not cor-
relate with severity of disease. As previously reported,
routine PJP prophylaxis does not appear to be necessary
[6]. For patients with poor antibody production, IVIG
can be considered. There are several case reports finding
benefit in using IVIG for acute infection or prophylaxis,
but no controlled studies exist at this time.
In addition to defects in the immune system, there are
also non-immunologic disease manifestations that must
be managed. Skin care focuses on reduction of bacterial
colonization on the skin. Frequent bleach baths followed
by moisturizing and adequate control of pruritus are
recommended. Optimizing vitamin D and calcium
intake is helpful for those patients with osteopenia. A
predilection towards aneurysms makes blood pressure
control important. Evaluation for retention of primary
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should also be monitoring for signs and symptoms of
lymphoma due to the increased incidence in AD-HIES.
These patients have a chronic disease that can result in
generalized or specific pain, depression, anxiety and fati-
gue. If chronic symptoms are affecting quality of life,
then complementary medicine such as acupuncture can
be attempted [25].
Hematopoietic stem cell tran s p l a n t( H S C T )i sg e n e r -
ally ineffective in type 1 HIES [26,27]. More recently,
however, myeloablative allogeneic HSCT proved effec-
tive in two unrelated boys with AD-HIES and non-
Hodgkin’s lymphoma who continue to have normal
immune reconstitution and no progression of non-
immunologic manifestations at follow-up 10 and 14
years [28].
Autosomal recessive forms
In addition to the autosomal dominant inheritance pat-
terns of HIES there are less prevalent forms of autosomal
recessive inheritance (Table 2). Tyrosine kinase 2 (TYK2)
defect was discovered in 2006 and dedicator of cytokinesis
8 protein (DOCK8) defect in 2009 [29,30]. These autoso-
mal recessive forms share some of the immunologic mani-
festations of AD-HIES but do not have the same non-
immunologic findings. TYK2-HIES has been described in
one patient and DOCK8-HIES has been described in <
100 patients to date. They both have recurrent cutaneous
and pulmonary bacterial and fungal infections, eczema,
eosinophilia and elevated IgE. TYK2-HIES does not have
development of pneumatoceles and both forms are distinct
given their susceptibility to viral infections such as herpes
and molluscum contagiosum [31]. Both forms are also
prone to allergic rhinitis and food allergies whereas this
finding is atypical in AD-HIES. DOCK8-HIES is also asso-
ciated with susceptibility to Salmonella and Giardia infec-
tions as well as development of early onset malignancies
and central nervous system vasculitis [31]. These patients
have a poor prognosis. Stem cell transplant has been suc-
cessful in DOCK8-HIES [32-34].
Our patient and another patient previously reported
by our group [35] were found to have significant
i n h a l a n ta n df o o ds e n s i t i v i t yw h i c hi su n c o m m o ni n
AD-HIES. The previously reported case had IgE sensiti-
zation proven by skin and serum testing as well as clini-
cal correlation by double-blind, placebo-controlled
challenge to cow’s milk. In both cases avoidance of milk
protein and usage of elemental formula was an effective
treatment.
Conclusions
This case underscores the inherent diagnostic difficulty
of HIES in young children with confounding co-morbid-
ities (food and inhalant allergies which are unusual fea-
tures for STAT3-HIES, transiently low IgA, aspiration
pneumonia, etc.). Clinical scoring systems establish
threshold scores for HIES suspicion: 40 and 30+IgE >
1,000 IU/ml, in the NIH-HIES and HIES STAT3 sys-
tems, respectively [1,2]. Utilizing clinical scoring systems
and maintaining an appropriate level of suspicion, clini-
cians can determine when STAT3 mutation analysis is
necessary. Availability of peripheral blood Th17 cell
enumeration at a clinical diagnostic laboratory would
allow for more expedient diagnosis and help to distin-
guish HIES from other diseases with elevated IgE,
namely atopic dermatitis [22]. Prophylactic therapy with
antibacterial and antifungal agents (when indicated) are
key points in patient management, along with regular
monitoring of vaccine titers and proactive vaccination.
This case of STAT3-HIES also highlights the inherent
susceptibility of these patients to intracellular organisms
endemic to the region (in our case, histoplasmosis). The
clinical course and outcome for our patient may be
instructive for other physicians managing patients with
STAT3-HIES.
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